Novel treatments for IPF

L. Richeldi (Southampton, United Kingdom)

Source: International Congress 2014 – ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)"

Session: ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)"
Session type: Symposium
Number: 2831

Disease area: Interstitial lung diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Richeldi (Southampton, United Kingdom). Novel treatments for IPF. International Congress 2014 – ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)"

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Common therapeutic approaches in IPF and lung cancer Source: Research Seminar 2015 Year: 2015
Novel therapeutics for CF Source: International Congress 2019 – Future of cystic fibrosis care: insights from the Lancet Commission Year: 2019
New treatment approaches for IPF Source: International Congress 2016 – ME2 New treatment approaches for idiopathic pulmonary fibrosis Year: 2016
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017
Treatment of COPD: from pharmacological to instrumental therapies Source: Eur Respir Rev 2009; 19: 7-23 Year: 2010
Potential new biomarkers for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020
Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009
Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019
IPF Source: Eur Respir Monogr 2017; 77: 199-223 Year: 2017
IPF Source: Eur Respir Monogr 2017; 77: 58-65 Year: 2017
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies Source: Eur Respir J, 53 (3) 1900283; 10.1183/13993003.00283-2019 Year: 2019
Novel therapeutics for cystic fibrosis Source: ERS Webinar 2020: Novel therapeutics for cystic fibrosis Year: 2020